Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
Protagonist Therapeutics develops peptide-based therapeutics using a proprietary discovery platform, with programs spanning inflammation and immunology, hematology and metabolic disease. Company news centers on ICOTYDE™ (icotrokinra), an oral IL-23 receptor-targeted peptide approved for moderate-to-severe plaque psoriasis, and rusfertide, a hepcidin mimetic peptide for polycythemia vera developed with Takeda.
Recurring updates also cover collaboration economics with Johnson & Johnson's Janssen Biotech and Takeda, clinical and regulatory milestones, R&D spending on wholly owned discovery programs, financial results, investor conference participation and equity-based inducement awards under Nasdaq rules.
On June 17, 2020, Protagonist Therapeutics (Nasdaq: PTGX) announced that the FDA granted Orphan Drug Designation for PTG-300, a synthetic peptide mimetic for treating polycythemia vera (PV). This milestone highlights PTG-300's potential to address patient needs in PV treatment. The Phase 2 results showed a robust clinical response with effective hematocrit control. The FDA’s designation provides benefits like marketing exclusivity and tax credits, vital for developing treatments for rare diseases affecting under 200,000 patients in the U.S.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced that Dinesh V. Patel, Ph.D., President and CEO, will participate in a fireside chat at the BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 1:00 p.m. EDT. The event will be accessible via a live and archived webcast on the company’s Investors section of its website. Protagonist is known for its proprietary technology platform aimed at developing novel peptide-based therapeutics, including three clinical-stage assets like PTG-300 and PTG-200.